Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more
Medifron DBT Co. Ltd (065650) - Total Assets
Latest total assets as of September 2025: ₩113.62 Billion KRW
Based on the latest financial reports, Medifron DBT Co. Ltd (065650) holds total assets worth ₩113.62 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medifron DBT Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medifron DBT Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Medifron DBT Co. Ltd's total assets of ₩113.62 Billion consist of 42.4% current assets and 57.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.62 Billion | 0.0% |
| Accounts Receivable | ₩11.86 Billion | 19.6% |
| Inventory | ₩1.44 Billion | 2.4% |
| Property, Plant & Equipment | ₩7.91 Billion | 13.1% |
| Intangible Assets | ₩130.75 Million | 0.2% |
| Goodwill | ₩6.99 Billion | 11.6% |
Asset Composition Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medifron DBT Co. Ltd's current assets represent 42.4% of total assets in 2024, an increase from 19.3% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 1.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 79.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 19.6% of total assets.
Medifron DBT Co. Ltd Competitors by Total Assets
Key competitors of Medifron DBT Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Medifron DBT Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Medifron DBT Co. Ltd generates 0.97x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medifron DBT Co. Ltd is currently not profitable relative to its asset base.
Medifron DBT Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.47 | 1.29 |
| Quick Ratio | 0.96 | 1.42 | 1.03 |
| Cash Ratio | 0.00 | 0.45 | 0.00 |
| Working Capital | ₩1.15 Billion | ₩ 16.03 Billion | ₩ 5.01 Billion |
Medifron DBT Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Medifron DBT Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.89 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.3% |
| Total Assets | ₩60.40 Billion |
| Market Capitalization | $11.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medifron DBT Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Medifron DBT Co. Ltd's assets grew by 8.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual total assets of Medifron DBT Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩60.40 Billion | +8.28% |
| 2023-12-31 | ₩55.79 Billion | +0.06% |
| 2022-12-31 | ₩55.75 Billion | +13.56% |
| 2021-12-31 | ₩49.10 Billion | +3.98% |
| 2020-12-31 | ₩47.22 Billion | +142.64% |
| 2019-12-31 | ₩19.46 Billion | -9.79% |
| 2018-12-31 | ₩21.57 Billion | -17.81% |
| 2017-12-31 | ₩26.24 Billion | -5.44% |
| 2016-12-31 | ₩27.75 Billion | -10.01% |
| 2015-12-31 | ₩30.84 Billion | +16.45% |
| 2014-12-31 | ₩26.48 Billion | -- |